Physician profile
Lauren M Yee
NPI 1669934204
$3,783.85
in general payments reported to CMS, 2019-2025
21 companies · $464 in 2025
The $464 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,240 · 2022: $176 · 2023: $977 · 2024: $926 · 2025: $464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,367.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gotham Surgical Solutions & Devices, INC. | $1,200.00 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $531.32 | 2022-2025 | Farxiga, Airsupra |
| Abbvie INC. | $474.86 | 2023-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $371.68 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $225.68 | 2023-2025 | |
| Lilly USA, LLC | $188.38 | 2022-2024 | Mounjaro, Emgality, Reyvow |
| Exact Sciences Corporation | $155.38 | 2023-2024 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.90 | 2022-2025 | Jardiance, Spiriva Respimat, Synjardy |
| Amgen INC. | $105.67 | 2023-2025 | Otezla, Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $70.57 | 2024 | Xarelto |
| Phathom Pharmaceuticals, INC. | $68.03 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $55.89 | 2021-2023 | Verquvo, Belsomra, Steglatro |
| Glaxosmithkline, LLC. | $50.13 | 2022-2023 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $38.66 | 2023 | |
| Corcept Therapeutics | $29.20 | 2023 | Korlym |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $24.19 | 2024 | Skyclarys |
| E.R. Squibb & Sons, L.L.C. | $20.09 | 2024 | Eliquis |
| Idorsia Pharmaceuticals US INC | $16.52 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.86 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $12.92 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $11.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Yee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.